Phathom Pharmaceuticals, Inc.
PHAT
$9.58
$0.404.36%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 27.40% | 1.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 27.40% | 1.25% | |||
| Cost of Revenue | 25.84% | 56.85% | |||
| Gross Profit | 27.80% | -7.27% | |||
| SG&A Expenses | 2.44% | 11.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.05% | 16.16% | |||
| Operating Income | 74.38% | -161.08% | |||
| Income Before Tax | 42.11% | -43.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.11% | -43.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 42.11% | -43.60% | |||
| EBIT | 74.38% | -161.08% | |||
| EBITDA | 74.94% | -164.95% | |||
| EPS Basic | 43.29% | -29.18% | |||
| Normalized Basic EPS | 43.28% | -29.15% | |||
| EPS Diluted | 43.29% | -29.18% | |||
| Normalized Diluted EPS | 43.28% | -29.15% | |||
| Average Basic Shares Outstanding | 2.07% | 11.15% | |||
| Average Diluted Shares Outstanding | 2.07% | 11.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||